Clinical TrialsThe company expects to dose their first patient in the 1L pivotal trial and will enroll about ~500 patients.
Financial OutlookCash and cash equivalents were reported at $846.4mn, providing a cash runway into 2028, inclusive of all planned trials.
Market PotentialThe only approved targeted treatment towards the EGFR PACC mutant class is afatinib, which has poor tolerability, and so there is a significant unmet clinical need.